Skip to main content
Top
Published in: Journal of Gastroenterology 2/2016

01-02-2016 | Original Article—Liver, Pancreas, and Biliary Tract

Evaluation of inflammation-based prognostic scores in patients undergoing hepatobiliary resection for perihilar cholangiocarcinoma

Authors: Masataka Okuno, Tomoki Ebata, Yukihiro Yokoyama, Tsuyoshi Igami, Gen Sugawara, Takashi Mizuno, Junpei Yamaguchi, Masato Nagino

Published in: Journal of Gastroenterology | Issue 2/2016

Login to get access

Abstract

Background

Inflammation-based prognostic scores have prognostic value in several kinds of cancer. However, little is known about their value in perihilar cholangiocarcinoma. We evaluated whether inflammation-based prognostic scores are associated with survival of patients with perihilar cholangiocarcinoma.

Methods

Inflammation-based scores (i.e., the modified Glasgow Prognostic Score (mGPS), neutrophil–lymphocyte ratio, platelet–lymphocyte ratio, and prognostic nutritional index) were retrospectively evaluated in 534 patients who underwent resection for perihilar cholangiocarcinoma. Blood samples obtained 1–3 days before surgery after jaundice had fully resolved with biliary drainage and after cholangitis had subsided were used to obtain the scores.

Results

Of the four scores evaluated, the mGPS showed prognostic value, whereas the remaining three scores did not. Patients with an mGPS of 0 had significantly better survival than patients with an mGPS of 1 or 2 (41.9 % vs 26.3 % at 5 years, P < 0.001). An mGPS of 1 or 2 was significantly associated with a higher incidence of preoperative cholangitis, node metastasis, and distant metastasis (pM). Irrespective of the absence (n = 442) or presence (n = 92) of preoperative cholangitis, the survival of patients with an mGPS of 0 was significantly better than that of patients with an mGPS of 1 or 2. Multivariate analysis revealed that the mGPS, blood transfusion, histologic grade, curability (R status), lymph node metastasis, and distant metastasis were independent prognostic factors.

Conclusions

As in other solid cancers, the mGPS is an independent prognostic factor in resected perihilar cholangiocarcinoma. This simple and inexpensive scoring system plays an important role in refining patient stratification and predicting survival.
Literature
1.
go back to reference Proctor MJ, Talwar D, Balmar SM, et al. The relationship between the presence and site of cancer, an inflammatory-based prognostic score and biochemical parameters: initial results of the Glasgow Inflammatory Outcome Study. Br J Cancer. 2010;103:870–6.PubMedCentralCrossRefPubMed Proctor MJ, Talwar D, Balmar SM, et al. The relationship between the presence and site of cancer, an inflammatory-based prognostic score and biochemical parameters: initial results of the Glasgow Inflammatory Outcome Study. Br J Cancer. 2010;103:870–6.PubMedCentralCrossRefPubMed
2.
go back to reference Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumor site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104:726–34.PubMedCentralCrossRefPubMed Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumor site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104:726–34.PubMedCentralCrossRefPubMed
3.
go back to reference Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer: a Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47:2633–41.CrossRefPubMed Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer: a Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47:2633–41.CrossRefPubMed
4.
go back to reference McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534–40.CrossRefPubMed McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534–40.CrossRefPubMed
5.
go back to reference Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91:181–4.CrossRefPubMed Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91:181–4.CrossRefPubMed
6.
go back to reference Malietzis G, Giacometti M, Askari A, et al. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann Surg. 2014;260:287–92.CrossRefPubMed Malietzis G, Giacometti M, Askari A, et al. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann Surg. 2014;260:287–92.CrossRefPubMed
7.
go back to reference Templeton AJ, McNamara MG, Seruqa B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.CrossRefPubMed Templeton AJ, McNamara MG, Seruqa B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.CrossRefPubMed
8.
go back to reference Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197:466–72.CrossRefPubMed Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197:466–72.CrossRefPubMed
9.
go back to reference Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyre ration (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12:58.PubMedCentralCrossRefPubMed Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyre ration (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12:58.PubMedCentralCrossRefPubMed
10.
go back to reference Onodera T, Goseki N, Kosaki G. (Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients). Nippon Geka Gakkai Zasshi. 1984;85:1001–5 (in Japanese with English abstract).PubMed Onodera T, Goseki N, Kosaki G. (Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients). Nippon Geka Gakkai Zasshi. 1984;85:1001–5 (in Japanese with English abstract).PubMed
11.
go back to reference Nozoe T, Kohno M, Iguchi T, et al. The prognostic nutritional index can be a prognostic indicator in colorectal carcinoma. Surg Today. 2012;42:532–5.CrossRefPubMed Nozoe T, Kohno M, Iguchi T, et al. The prognostic nutritional index can be a prognostic indicator in colorectal carcinoma. Surg Today. 2012;42:532–5.CrossRefPubMed
12.
go back to reference Kanda M, Fujii T, Kodera Y, et al. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011;98:268–74.CrossRefPubMed Kanda M, Fujii T, Kodera Y, et al. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011;98:268–74.CrossRefPubMed
13.
14.
go back to reference Ebata T, Kamiya J, Nishio H, et al. The concept of perihilar cholangiocarcinoma is valid. Br J Surg. 2009;96:926–34.CrossRefPubMed Ebata T, Kamiya J, Nishio H, et al. The concept of perihilar cholangiocarcinoma is valid. Br J Surg. 2009;96:926–34.CrossRefPubMed
15.
go back to reference Nagino M, Nimura Y, Nishio H, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg. 2010;252:115–23.CrossRefPubMed Nagino M, Nimura Y, Nishio H, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg. 2010;252:115–23.CrossRefPubMed
16.
go back to reference Lee SG, Song GW, Hwang S, et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Surg. 2010;17:476–89.CrossRef Lee SG, Song GW, Hwang S, et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Surg. 2010;17:476–89.CrossRef
17.
go back to reference van Gulik TM, Kloek JJ, Ruys AT, Busch ORC, van Tienhoven GJ, Lameris JS, et al. Multidisciplinary management of hilar cholangiocarcinoma (Klatskin tumor): extended resection is associated with improved survival. Eur J Surg Oncol. 2011;37:65–71.CrossRefPubMed van Gulik TM, Kloek JJ, Ruys AT, Busch ORC, van Tienhoven GJ, Lameris JS, et al. Multidisciplinary management of hilar cholangiocarcinoma (Klatskin tumor): extended resection is associated with improved survival. Eur J Surg Oncol. 2011;37:65–71.CrossRefPubMed
18.
go back to reference Young AL, Igami T, Senda Y, et al. Evolution of the surgical management of perihilar cholangiocarcinoma in a Western center demonstrates improved survival with endoscopic biliary drainage and reduced use of blood transfusion. HPB (Oxf). 2011;13:483–93.CrossRef Young AL, Igami T, Senda Y, et al. Evolution of the surgical management of perihilar cholangiocarcinoma in a Western center demonstrates improved survival with endoscopic biliary drainage and reduced use of blood transfusion. HPB (Oxf). 2011;13:483–93.CrossRef
19.
go back to reference Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258:129–40.CrossRefPubMed Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258:129–40.CrossRefPubMed
20.
go back to reference Dumitrascu T, Chirta D, Lonescu M, et al. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg. 2013;17:913–24.CrossRefPubMed Dumitrascu T, Chirta D, Lonescu M, et al. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg. 2013;17:913–24.CrossRefPubMed
21.
go back to reference Oshiro Y, Sasaki R, Fukunaga K, et al. Inflammation-based prognostic score is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2013;20:389–95.CrossRefPubMed Oshiro Y, Sasaki R, Fukunaga K, et al. Inflammation-based prognostic score is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2013;20:389–95.CrossRefPubMed
22.
go back to reference Kawashima H, Itoh A, Ohno E, et al. Preoperative endoscopic nasobiliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma: a retrospective study of efficacy and risk factors related to complications. Ann Surg. 2013;257:121–7.CrossRefPubMed Kawashima H, Itoh A, Ohno E, et al. Preoperative endoscopic nasobiliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma: a retrospective study of efficacy and risk factors related to complications. Ann Surg. 2013;257:121–7.CrossRefPubMed
23.
go back to reference Kanai M, Nimura Y, Kamiya J, et al. Preoperative intrahepatic segmental cholangitis in patients with advanced carcinoma involving the hepatic hilus. Surgery. 1996;119:498–504.CrossRefPubMed Kanai M, Nimura Y, Kamiya J, et al. Preoperative intrahepatic segmental cholangitis in patients with advanced carcinoma involving the hepatic hilus. Surgery. 1996;119:498–504.CrossRefPubMed
24.
go back to reference Yokoyama Y, Ebata T, Igami T, et al. The adverse effects of preoperative cholangitis on the outcome of portal vein embolization and subsequent major hepatectomies. Surgery. 2014;156(5):1190–6.CrossRefPubMed Yokoyama Y, Ebata T, Igami T, et al. The adverse effects of preoperative cholangitis on the outcome of portal vein embolization and subsequent major hepatectomies. Surgery. 2014;156(5):1190–6.CrossRefPubMed
25.
go back to reference Kamiya S, Nagino M, Kanazawa H, et al. The value of bile replacement during external biliary drainage: an analysis of intestinal permeability, integrity, and microflora. Ann Surg. 2004;239:510–7.PubMedCentralCrossRefPubMed Kamiya S, Nagino M, Kanazawa H, et al. The value of bile replacement during external biliary drainage: an analysis of intestinal permeability, integrity, and microflora. Ann Surg. 2004;239:510–7.PubMedCentralCrossRefPubMed
26.
go back to reference Nagino M, Nimura Y, Kamiya J, et al. Selective percutaneous transhepatic embolization of the portal vein in preparation for extensive liver resection: the ipsilateral approach. Radiology. 1996;200:559–63.CrossRefPubMed Nagino M, Nimura Y, Kamiya J, et al. Selective percutaneous transhepatic embolization of the portal vein in preparation for extensive liver resection: the ipsilateral approach. Radiology. 1996;200:559–63.CrossRefPubMed
27.
go back to reference Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006;243:364–72.PubMedCentralCrossRefPubMed Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006;243:364–72.PubMedCentralCrossRefPubMed
28.
go back to reference Ebata T, Yokoyama Y, Igami T, et al. Hepatopancreatoduodenectomy for cholangiocarcinoma: a single center review of 85 consecutive patients. Ann Surg. 2012;256:297–305.CrossRefPubMed Ebata T, Yokoyama Y, Igami T, et al. Hepatopancreatoduodenectomy for cholangiocarcinoma: a single center review of 85 consecutive patients. Ann Surg. 2012;256:297–305.CrossRefPubMed
29.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedCentralCrossRefPubMed Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedCentralCrossRefPubMed
30.
go back to reference Gerhardt T, Milz S, Schpke M, et al. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol. 2006;12:5495–500.PubMedCentralPubMed Gerhardt T, Milz S, Schpke M, et al. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol. 2006;12:5495–500.PubMedCentralPubMed
31.
go back to reference McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90:215–9.CrossRefPubMed McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90:215–9.CrossRefPubMed
32.
go back to reference Castell JV, Gómez-Lechón MJ, David M, et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–86.CrossRefPubMed Castell JV, Gómez-Lechón MJ, David M, et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–86.CrossRefPubMed
33.
go back to reference Okada K, Shimizu Y, Nambu S, et al. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol. 1994;9:462–7.CrossRefPubMed Okada K, Shimizu Y, Nambu S, et al. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol. 1994;9:462–7.CrossRefPubMed
34.
go back to reference Nozoe T, Iguchi T, Egashira A, et al. Significance of modified Glasgow score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg. 2011;201:186–91.CrossRefPubMed Nozoe T, Iguchi T, Egashira A, et al. Significance of modified Glasgow score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg. 2011;201:186–91.CrossRefPubMed
35.
go back to reference Jiang X, Hiki N, Nunobe S, et al. Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer. 2012;107:275–9.PubMedCentralCrossRefPubMed Jiang X, Hiki N, Nunobe S, et al. Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer. 2012;107:275–9.PubMedCentralCrossRefPubMed
36.
go back to reference Wang DS, Ren C, Qui MZ, et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumor Biol. 2012;33:749–56.CrossRef Wang DS, Ren C, Qui MZ, et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumor Biol. 2012;33:749–56.CrossRef
37.
go back to reference Ishizuka M, Nagata H, Takagi K, et al. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246:1047–51.CrossRefPubMed Ishizuka M, Nagata H, Takagi K, et al. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246:1047–51.CrossRefPubMed
38.
go back to reference Letch FF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97:1266–70.CrossRef Letch FF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97:1266–70.CrossRef
39.
go back to reference Choi KW, Hong SW, Chang YG, et al. Inflammation-based score (Glasgow prognostic score) as an independent prognostic factor in colorectal cancer patients. Ann Surg Treat Res. 2014;86:309–13.PubMedCentralCrossRefPubMed Choi KW, Hong SW, Chang YG, et al. Inflammation-based score (Glasgow prognostic score) as an independent prognostic factor in colorectal cancer patients. Ann Surg Treat Res. 2014;86:309–13.PubMedCentralCrossRefPubMed
40.
go back to reference Nagino M. Perihilar cholangiocarcinoma: surgeon’s view point on current topics. J Gastroenterol. 2012;47:1165–76.CrossRefPubMed Nagino M. Perihilar cholangiocarcinoma: surgeon’s view point on current topics. J Gastroenterol. 2012;47:1165–76.CrossRefPubMed
Metadata
Title
Evaluation of inflammation-based prognostic scores in patients undergoing hepatobiliary resection for perihilar cholangiocarcinoma
Authors
Masataka Okuno
Tomoki Ebata
Yukihiro Yokoyama
Tsuyoshi Igami
Gen Sugawara
Takashi Mizuno
Junpei Yamaguchi
Masato Nagino
Publication date
01-02-2016
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 2/2016
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-015-1103-y

Other articles of this Issue 2/2016

Journal of Gastroenterology 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.